Table 2.
Comparison of treatment responses between the Prog group and the Prog+Met group.
| Prog | Prog+Met | P-value | |
|---|---|---|---|
| N = 138 patients | N = 81 patients | ||
| CR+PR, rate, %(n) | 87.7% (121/138) | 97.5% (79/81) | P=0.024 |
| CR,rate, %(n) | 84.1% (116/138) | 93.8% (76/81) | P=0.034 |
| NR,rate, %(n) | 11.6% (16/138) | 2.5% (2/81) | P=0.034 |
| PD, rate, %(n) | 0.7% (1/138) | 0% (0/81) | P=1.000 |
| Incidence of adverse effects, %(n) | 0.7% (1/138)) | 4.9% (4/81) | P=0.122 |
Prog, progesterone; Met, metformin; CR, complete response; PR, partial response; NR, no response; PD, progressive disease.